What's Happening?
Sustained Therapeutics has presented positive Phase 2 data for its non-opioid therapy, ST-01, at the American Urological Association 2026 Annual Meeting. The study involved 63 men with chronic scrotal content pain (CSCP) and demonstrated significant pain reduction
at a 70 mg/mL dose compared to standard care. The treatment was well tolerated, with 67% of patients achieving a significant reduction in pain scores. The company plans to advance ST-01 to Phase 3 development, aiming to provide a non-surgical treatment option for CSCP, a condition affecting millions with limited current therapies.
Why It's Important?
The success of ST-01 in reducing chronic scrotal content pain offers a promising alternative to opioid-based treatments, addressing a significant unmet need in urology. This development could lead to improved quality of life for patients and reduce reliance on invasive procedures and opioid medications. The therapy's potential to provide durable pain relief could transform treatment approaches for chronic urologic pain, benefiting both patients and healthcare providers by offering a safer, more effective option.
What's Next?
Sustained Therapeutics plans to move forward with Phase 3 trials for ST-01, subject to regulatory review. The company is also exploring the broader applicability of its sustained-release platform for other chronic pain conditions, such as chronic pelvic pain. Continued success in clinical trials could lead to regulatory approval and commercialization, providing a new therapeutic option for patients and potentially reducing healthcare costs associated with chronic pain management.
